C-peptide vs Omentin-1
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | Omentin-1 |
|---|---|---|
| Category | Pain Management | Diabetes & Metabolic |
| Full Name | Connecting peptide (C-peptide) | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 3020.3 Da | ~35 kDa |
| Half-Life | ~20-30 min | hours |
| Amino Acids | 31 | 313 |
| Typical Dose | no approved analgesic dose|research-only | No approved human dose; research use only |
| Route | IV|subQ | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 82 |
| Research Status | Pre-clinical | Pre-clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Omentin-1 Dosing
not established|not established
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.